Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma

BACKGROUND: The phase 3 CheckMate 214 trial demonstrated higher response rates and improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line therapy for advanced clear-cell renal cell carcinoma (RCC). An unmet need exists to identify patients with RCC who are most likel...

Descripción completa

Detalles Bibliográficos
Autores principales: Motzer, Robert J, Choueiri, Toni K, McDermott, David F, Powles, Thomas, Vano, Yann-Alexandre, Gupta, Saurabh, Yao, Jin, Han, Celine, Ammar, Ron, Papillon-Cavanagh, Simon, Saggi, Shruti S, McHenry, M Brent, Ross-Macdonald, Petra, Wind-Rotolo, Megan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935174/
https://www.ncbi.nlm.nih.gov/pubmed/35304405
http://dx.doi.org/10.1136/jitc-2021-004316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935174/
https://www.ncbi.nlm.nih.gov/pubmed/35304405
http://dx.doi.org/10.1136/jitc-2021-004316

Ejemplares similares